The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / S•••••

P•••••• R••••• Acquires the S••••• and Marketing of Paraformaldehyde and Hexamethylenetetramine from E•••

Add-on acquisitionannouncedadd-onannounced Oct 2, 2023Fact
What happened
Target
S•••••
Platform
P•••••• R•••••add-on basis: P•••••• R••••• Acquires the S••••• and Marketing of Paraformaldehyde and Hexamethylenetetramine from E••• | P•••••• R••••• Holding GmbH is held by O•• R••• C•••••• on its portfolio page; published on O•• R••• C••••••'s own news page
Control
Control
Share acquired
unknown
Industry
business_services / marketing
Target location
unknown
Seller kind
Unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
6 named
Buy side
  • P•••••• R•••••Platformconfirmed
    “P•••••• R••••• Acquires the S••••• and Marketing of Paraformaldehyde and Hexamethylenetetramine from E••• | P•••••• R••••• Holding GmbH is held by O•• R••• C•••••• on its portfolio page; published on O•• R••• C••••••'s own news page”
  • O•• R••• C••••••Sponsorderived
    “P•••••• R••••• Acquires the S••••• and Marketing of Paraformaldehyde and Hexamethylenetetramine from E••• | P•••••• R••••• Holding GmbH is held by O•• R••• C•••••• on its portfolio page; published on O•• R••• C••••••'s own news page”
Sell side
Side not stated
  • E•••• B••••Managementconfirmed
    “E•••• B••••, CEO of P•••••• R•••••, commented, “We are very excited about the acquisition of E•••’ Paraformaldehyde & Hexamethylenetetramine customer base, and we are confident that this opportunity will renew our strong commitment to the Paraform business.”
  • C•••••••• R••••Managementconfirmed
    “C•••••••• R••••, Melamine and Paraform Business Unit Leader of P•••••• R•••••, added, “This transaction ensures existing E••• customers a seamless and smooth transition without interruption to their businesses.”
  • S•••••Targetconfirmed
    “P•••••• R••••• Acquires the S••••• and Marketing of Paraformaldehyde and Hexamethylenetetramine from E•••”
Evidence
“P•••••• R••••• Acquires the S••••• and Marketing of Paraformaldehyde and Hexamethylenetetramine from E•••”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
P•••••• R••••• Acquires the S••••• and Marketing of Paraformaldehyde and Hexamethylenetetr | Private Equity Intelligence | DFX